Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Scotland says no to Yescarta, but backs KymriahScotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types Share XScotland says no to Yescarta, but backs Kymriahhttps://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/
Gilead needs deal-maker CEO after Milligan quitsGilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of Share XGilead needs deal-maker CEO after Milligan quitshttps://pharmaphorum.com/news/gilead-needs-deal-maker-ceo-after-milligan-quits-analyst/
Hep C woes to continue – but Gilead willing to acquire againGilead recorded a loss of $3.9 billion in Q4 because of a one-off charge linked to US tax Share XHep C woes to continue – but Gilead willing to acquire againhttps://pharmaphorum.com/news/hep-c-woes-continue-gilead-willing-acquire/
